Literature DB >> 26929061

Methamphetamine-associated cardiomyopathy: patterns and predictors of recovery.

A Voskoboinik1, J F Ihle2, J E Bloom1, D M Kaye1,3.   

Abstract

BACKGROUND: Methamphetamine abuse is a growing public health problem, and increasing numbers of patients are admitted with methamphetamine-associated cardiomyopathy (MAC). AIM: We sought to characterise the patterns of this disease and identify predictors of recovery.
METHODS: We retrospectively studied consecutive patients diagnosed with MAC between January 2006 and July 2015.
RESULTS: We identified 20 patients (14 males, 6 females) with mean age 35 ± 9 years. Most had very severe systolic dysfunction (mean left ventricular ejection fraction (LVEF) 19.7 ± 11.4%) at presentation with 14 requiring inotropes and 5 requiring mechanical support. The pattern of systolic dysfunction was global in 14 patients, while 6 patients had a 'reverse Takotsubo' (RT) pattern with severely hypokinetic basal-mid segments and apical preservation. RT patients were predominantly female, had a short history of methamphetamine abuse and had higher cardiac enzyme levels. Patients with global dysfunction tended to have mid-wall fibrosis on cardiac magnetic resonance imaging. On follow-up transthoracic echocardiography, 6 out of 19 (32%) had normalisation of LVEF (LVEF ≥ 50%) within 6 weeks. Smaller left ventricular and left atrial size, shorter duration of methamphetamine use and RT pattern appeared to predict early recovery.
CONCLUSION: A subset of MAC patients, particularly those with a RT pattern and lesser ventricular dilatation have the potential for early recovery of ventricular function. By contrast, those with evidence of myocardial fibrosis and ventricular enlargement have limited scope for recovery.
© 2016 Royal Australasian College of Physicians.

Entities:  

Keywords:  cardiomyopathy; heart failure; methamphetamine; reverse Takotsubo

Mesh:

Substances:

Year:  2016        PMID: 26929061     DOI: 10.1111/imj.13050

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  8 in total

1.  The emergence of cardiac changes following the self-administration of methamphetamine.

Authors:  Jessica L Freeling; Lisa M McFadden
Journal:  Drug Alcohol Depend       Date:  2020-04-23       Impact factor: 4.492

Review 2.  A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy.

Authors:  Michael Osekowski; Adam Trytell; Andre La Gerche; David Prior; Andrew MacIsaac; Elizabeth D Paratz
Journal:  Am J Cardiovasc Drugs       Date:  2022-02-14       Impact factor: 3.283

3.  Reverse Takotsubo Cardiomyopathy After Accidental Exposure to an Illicit Substance: A Case Report.

Authors:  Charles White; Rebecca Jeanmonod
Journal:  Cureus       Date:  2022-04-19

4.  Acute onset heart failure due to reverse type Takotsubo cardiomyopathy caused by a single dose of 4-Fluoroamphetamine in a healthy young individual.

Authors:  R S D van der Pas; F M J Gresnigt; L Wansink; E J F Franssen; R K Riezebos
Journal:  Toxicol Rep       Date:  2020-12-03

5.  Hemodynamic Effects of Methamphetamine and General Anesthesia.

Authors:  Keyvan M Safdari; Curtis Converse; Fanglong Dong; Nickolas Alan MacDougall; Kevin Hyer; Alec Runyon; Haley Ahlering; Mark E Comunale
Journal:  Anesthesiol Res Pract       Date:  2022-02-17

6.  Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis.

Authors:  Ekaterina S Prokudina; Boris K Kurbatov; Konstantin V Zavadovsky; Alexander V Vrublevsky; Natalia V Naryzhnaya; Yuri B Lishmanov; Leonid N Maslov; Peter R Oeltgen
Journal:  Curr Cardiol Rev       Date:  2021

Review 7.  Clinical Characteristics and Management of Methamphetamine-Associated Cardiomyopathy: State-of-the-Art Review.

Authors:  Pavan K V Reddy; Tien M H Ng; Esther E Oh; Gassan Moady; Uri Elkayam
Journal:  J Am Heart Assoc       Date:  2020-05-29       Impact factor: 5.501

Review 8.  Methamphetamine-related cardiovascular diseases.

Authors:  Valentin Schwarzbach; Karsten Lenk; Ulrich Laufs
Journal:  ESC Heart Fail       Date:  2020-01-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.